哈尔滨敷尔佳科技股份有限公司 舆情管理制度 第一章 总则 第一条 为进一步提高哈尔滨敷尔佳科技股份有限公司（以下简称"公司"） 应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情 对公司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合 法权益，根据《深圳证券交易所创业板股票上市规则》等相关法律法规和《哈尔 滨敷尔佳科技股份有限公司章程》（以下简称"《公司章程》"）的规定，特制 定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动， 使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易价格变 动的负面舆情； （二）一般舆情：指除重大舆情之外的其他舆情。 第四条 公司舆情管理工作坚持"统一指挥、快速反应、尊重事实、协 ...

证券代码：301371 证券简称：敷尔佳 公告编号：2024-062 哈尔滨敷尔佳科技股份有限公司 第二届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三、备查文件 1、第二届监事会第七次会议决议。 1 一、监事会会议召开情况 哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）第二届监事会第七次 会议于 2024 年 11 月 5 日以通讯方式召开。本次会议通知已于 2024 年 11 月 2 日 以通讯方式发出，本次会议应出席监事 3 人，实际出席监事 3 人。会议由监事会 主席许小明先生主持，公司董事会秘书列席了本次会议。会议召开符合法律法规、 《公司法》及《公司章程》的规定。 二、监事会会议审议情况 1、审议通过《关于使用节余募集资金及超募资金并调整募投项目投资金额的 议案》 公司监事会认为，本次使用节余募集资金和超募资金并调整募投项目投资金 额，是根据公司募投项目建设及募集资金实际使用情况做出的合理安排，有利于 提高募集资金使用效率及合理性，不存在损害公司及股东利益的情形，同意本次 使用节余募集资金和超募资金并调整募投项目投资 ...

证券代码：301371 证券简称：敷尔佳 公告编号：2024-064 哈尔滨敷尔佳科技股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《哈尔滨敷尔佳科技股份有限公司章程》 （以下简称"《公司章程》"）等相关规定，哈尔滨敷尔佳科技股份有限公司（以 下简称"公司"）于 2024 年 11 月 5 日召开第二届董事会第九次会议，审议通过 了《关于提请召开公司 2024 年第二次临时股东大会的议案》，决定于 2024 年 11 月 22 日（星期五）以现场表决与网络投票相结合的方式召开公司 2024 年第二次 临时股东大会，现将会议有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年第二次临时股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召集、召开符合有关法律、 行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2024 年 11 月 22 日（星期五）下午 1 ...

证券代码：301371 证券简称：敷尔佳 公告编号：2024-061 哈尔滨敷尔佳科技股份有限公司 第二届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）第二届董事会第九次会 议于 2024 年 11 月 5 日以通讯方式召开。本次会议通知已于 2024 年 11 月 2 日以通 讯方式发出，本次会议应出席董事 5 名，实际出席董事 5 名，会议由公司董事长张 立国先生主持，公司监事及高级管理人员列席了本次会议。会议召开符合法律法规、 《公司法》及《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于使用节余募集资金及超募资金并调整募投项目投资金额的 议案》 公司根据募投项目实际建设情况，将"生产基地建设项目"与"研发及质量检 测中心建设项目"节余资金及全部超募资金（以上资金包含利息收入和现金管理收 益扣除手续费后的净额，具体金额以实际结转时募集资金账户余额为准）投入至"品 牌营销推广项目"，有利于优化资金和资源配置，提高资金使用效率及合理性，同 意公司 ...

Investment Rating - The investment rating for the company is "Buy" with a target price reflecting a potential upside of over 20% within the next six months [3][11]. Core Views - The company reported Q3 revenue of 527 million, representing a year-over-year increase of 11.88%, indicating steady growth [1]. - The company is expanding its medical beauty business, with a new product that has passed ethical review and is set to enter clinical trials, which is significant for market expansion and product line diversification [1]. - The company is expected to improve its market share due to its strong online and offline channel capabilities, alongside enhanced product, brand, and marketing strength [2]. Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 1.466 billion, a year-over-year increase of 9.47%, with a net profit of 514 million, down 4.2% year-over-year [1]. - The gross margin for Q3 2024 was 82.07%, up 0.5 percentage points year-over-year, while the gross margin for the first three quarters was 81.65%, down 0.7 percentage points year-over-year [1]. - Sales expenses increased by 38.5% year-over-year due to higher marketing and e-commerce investments, while R&D expenses surged by 100.8% as the company focuses on innovation [1]. Financial Forecasts - The projected net profit for 2024-2026 is 739.85 million, 805.43 million, and 897.80 million respectively, with corresponding P/E ratios of 20, 18, and 16 times [2][5]. - Revenue forecasts for 2024-2026 are 2.146 billion, 2.399 billion, and 2.694 billion respectively, with growth rates of 11%, 11.8%, and 12.3% [2][5]. - The company’s EBITDA for 2024-2026 is expected to be 978.67 million, 1.09586 billion, and 1.23051 billion respectively [2][5].

证券代码：301371 证券简称：敷尔佳 哈尔滨敷尔佳科技股份有限公司 投资者关系活动记录表 编号：2024-008 | --- | --- | --- | --- | --- | |--------------|--------------------------------------------------------|----------------------------------------------------|-------|-------| | | ☑ 特定对象调研 | 分析师会议 | | | | | □媒体采访 | 业绩说明会 | | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | | 动类别 | ☑ 现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | | 黑龙江证券业协会 副秘书长 孔馨莹 | | | | | | 黑龙江证券业协会 权益部副主任 | | 杜 | 莹 | | 参与单位名称 | 国泰君安黑龙江分公司 | 副总经理 黄 波 | | | | 及人员姓名 | 国泰君安哈尔滨兴江路营业部 | 总经理 吴 | | 迪 | | ...

Investment Rating - The report downgrades the company's rating to "Overweight" from a previous rating, reflecting a cautious outlook on its future performance [3][7] Core Views - The company achieved a revenue of 1.47 billion yuan in the first three quarters of 2024, a year-on-year increase of 9.5%, but net profit attributable to the parent company declined by 4.2% to 510 million yuan [1] - The decline in profitability is attributed to a decrease in gross margin and an increase in expense ratio, with the net profit margin dropping by 5.0 percentage points to 35.0% [1] - In Q3 2024, the company's revenue grew by 11.9% year-on-year to 530 million yuan, while net profit attributable to the parent company fell by 5.2% to 170 million yuan [1] - The company's gross margin for the first three quarters of 2024 decreased by 0.7 percentage points to 81.6%, with Q3 showing a slight improvement of 0.5 percentage points compared to the previous quarters [2] - The expense ratio increased by 6.6 percentage points to 35.3%, driven by higher sales expenses due to increased marketing and e-commerce channel investments [2] - Inventory as of September 2024 increased by 17.2% compared to the beginning of the year, reaching 140 million yuan, while accounts receivable decreased significantly by 95.82% to 760,000 yuan [2] - Operating cash flow for the first three quarters decreased by 19.8% to 470 million yuan [2] Financial Performance - The company's medical device and cosmetics revenue grew by approximately 17% and 4% year-on-year, respectively, in the first three quarters of 2024 [3] - The company now has six products with sales exceeding 100 million yuan, with new products such as eye masks and grape seed masks performing well [3] - Online sales grew faster compared to the same period last year, while offline sales showed steady growth [3] - The company's EPS for 2024/2025/2026 is forecasted to be 1.79/1.96/2.15 yuan, with corresponding P/E ratios of 20/18/17 times [3] - The report revised the company's profit forecasts downward, with net profit attributable to the parent company for 2024 and 2025 reduced by 15% and 13%, respectively [3] Market Data - The company's total market capitalization is 14.52 billion yuan, with a total share capital of 400 million shares [8] - The stock price range over the past year was between 24.47 yuan and 48.63 yuan, with a 3-month turnover rate of 23.59% [8] Financial Projections - Revenue for 2024E/2025E/2026E is projected to be 2.13/2.36/2.59 billion yuan, with growth rates of 10.22%/10.52%/9.81% [4] - Net profit for 2024E/2025E/2026E is expected to be 715/786/859 million yuan, with growth rates of -4.53%/9.89%/9.32% [4] - ROE (diluted) for 2024E/2025E/2026E is forecasted to be 12.09%/12.43%/12.70% [4] - The company's P/B ratio for 2024E/2025E/2026E is projected to be 2.5/2.3/2.1 times [4]

Investment Rating - The report maintains an "Accumulate" rating for the company [2] Core Views - The company has shown a significant revenue growth in Q3, with a year-on-year increase of 11.88% to reach 527 million yuan, while the net profit for the same period was 173 million yuan, reflecting a decrease of 5.16% [4] - The company is focusing on strong R&D efforts, with R&D expenses increasing by 100% year-on-year to 31 million yuan, which supports the rapid introduction of new products [4] - The online sales channel is driving performance, with notable growth during promotional events, such as a 26% increase in GMV on Tmall and a 103% increase on Douyin during the pre-sale period [5] Financial Performance Summary - For the first three quarters of 2024, the company achieved a revenue of 1.466 billion yuan, representing a 9.47% increase, with a gross margin of 81.65% [4] - The net profit for the first three quarters was 514 million yuan, down 4.20% year-on-year, with a net profit margin of 35.03% [4] - The company expects revenues of 2.130 billion yuan, 2.387 billion yuan, and 2.658 billion yuan for 2024, 2025, and 2026 respectively, with growth rates of 10.2%, 12.1%, and 11.3% [5][6] Product Development and Market Strategy - The company is actively expanding its product matrix, launching multiple new products in Q3, including various masks and serums that utilize advanced technology [4] - The company is enhancing its product development capabilities, with ongoing research on innovative ingredients and formulations, such as humanized collagen products [4] - The report highlights the company's strategic focus on e-commerce, which is expected to provide substantial growth opportunities [5]

Investment Rating - The report maintains a "Recommended" rating for the company [4]. Core Views - The company has demonstrated a steady increase in revenue, with a year-on-year growth of 11.9% in Q3 2024, indicating a gradual enhancement of brand and product strength [2]. - The company is expected to achieve revenues of 2.133 billion, 2.359 billion, and 2.595 billion yuan for the years 2024, 2025, and 2026, respectively, reflecting growth rates of 10.3%, 10.6%, and 10.0% [3][6]. - The net profit attributable to the parent company is projected to be 714 million, 783 million, and 854 million yuan for the same years, with growth rates of -4.7%, 9.7%, and 9.0% [3][6]. Financial Performance Summary - For the first three quarters of 2024, the company achieved a total revenue of 1.466 billion yuan, a year-on-year increase of 9.47%, and a net profit of 514 million yuan, a decrease of 4.20% [2]. - The gross margin for Q1-Q3 2024 was 81.65%, a decrease of 0.73 percentage points year-on-year, while the gross margin for Q3 2024 was 82.07%, an increase of 0.48 percentage points year-on-year [2]. - The net profit margin for Q1-Q3 2024 was 35.03%, down 5.00 percentage points year-on-year, and for Q3 2024, it was 32.91%, down 5.91 percentage points year-on-year [2]. Product and Market Strategy - The company is focusing on enhancing its competitive edge through a multi-dimensional approach involving product development, channel expansion, and marketing efforts [2]. - The company has successfully launched over ten new products in August 2024, including innovative skincare items utilizing advanced technology [2]. - The company is expanding its presence in both offline and online sales channels, ensuring comprehensive coverage across various platforms [2]. Future Outlook - The company is expected to continue increasing its market share in the functional skincare and medical device sectors, supported by ongoing investments in research and development [2]. - The report anticipates a steady growth trajectory for the company, with a focus on enhancing brand recognition and product offerings [2].

证券代码：301371 证券简称：敷尔佳 哈尔滨敷尔佳科技股份有限公司 投资者关系活动记录表 编号：2024-007 | --- | --- | --- | --- | --- | --- | --- | |--------------|-----------------------|----------------------------|-------|-------|-------|-------| | | | | | | | | | | ☑ 特定对象调研 | 分析师会议 | | | | | | | □媒体采访 | 业绩说明会 | | | | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | | | | 动类别 | □现场参观 | | | | | | | | □其他 | （请文字说明其他活动内容） | | | | | 参与单位名称 | --- | --- | |---------------------------|-----------------------------------------------------------------| | | | | 及人员姓名 | 中信证 ...